CN101282936B - Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same - Google Patents

Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same Download PDF

Info

Publication number
CN101282936B
CN101282936B CN2006800373585A CN200680037358A CN101282936B CN 101282936 B CN101282936 B CN 101282936B CN 2006800373585 A CN2006800373585 A CN 2006800373585A CN 200680037358 A CN200680037358 A CN 200680037358A CN 101282936 B CN101282936 B CN 101282936B
Authority
CN
China
Prior art keywords
expression
alkyl
halogen atom
yield
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800373585A
Other languages
Chinese (zh)
Other versions
CN101282936A (en
Inventor
丰岛贵弘
佐佐木俊信
星野力
竹田雅一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of CN101282936A publication Critical patent/CN101282936A/en
Application granted granted Critical
Publication of CN101282936B publication Critical patent/CN101282936B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Abstract

The present invention relates to novel compounds having a xanthine oxidase inhibitory effect and a uricosuric effect and pharmaceutical compositions comprising the same as an active ingredient. That is, the present invention relates nitrogen-containing heterocyclic compounds represented by the following general formula (I): wherein Y<1> represents N or C(R<4>); Y<2> represents N or C(R<5>); R<4> and R<5> independently represent an alkyl group, a hydrogen atom etc.; one of R<1> and R<2> represents an optionally substituted aryl group, an alkoxy group or an optionally substituted heterocyclic group; the other of R<1> and R<2> represents a haloalkyl group, a cyano group, a halogen atom etc.; and R<3> represents a 5-tetrazolyl group or a carboxy group, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same as an active ingredient.

Description

Nitrogenize heterogeneous ring compound and comprise its pharmaceutical composition
Technical field
The present invention relates to nitrogen-containing heterocycle compound and contain its pharmaceutical composition.More particularly, the pharmaceutical composition that the present invention relates to have the nitrogen-containing heterocycle compound of XOD restraining effect and uricosuric Excretion and contain it.
Background technology
The major cause of hyperuricemia is that the generation of uric acid increases and drainage reduces.The former mainly is by due to the excessive generation uric acid of XOD (hereinafter being also referred to as X.O.).On the other hand, the latter heavily absorbs increase for the uriniferous tubules of uric acid, and the rise of dominant mechanism behaviour uric acid transporter (hereinafter being also referred to as URAT1).Because uric acid is slightly soluble in water, therefore caused hyperuricemia.When the uric acid in the blood was too much, the crystallization uric acid is deposition in joint etc., has caused the acute invasion and attack of sacroiliitis (gout) or the chronic change in bone and joint thus.In addition, the complication like urinary stone and renal insufficiency (gout kidney) also becomes problem.
Current, as the therapeutical agent of gout and hyperuricemia, the Zyloric (alloprinol) that is widely used, a kind of X.O. suppressor factor.In addition, in references 1-4, disclose have X.O. inhibiting be used for hyperuricemia other the treatment reagent.Also use and have the benzbromarone that uric acid heavily absorbs restraining effect (uricosuric Excretion).As another kind of medicament, the probenecid of also having given an example, but owing to often do not use a little less than its activity.In addition, the biaryl compound of description in the references 5 or the medicament that the conduct of diaryl ether compound has the uricosuric Excretion have been reported.
Japanese Patent No.3399559 specification sheets.
Japanese Patent No.3220987 specification sheets.
Japanese patent publication No.2002-105067 communique.
International Publication No. WO 03/064410 pph.
Japanese patent publication No.2000-001431 communique.
Disclosure of the Invention
The problem that the present invention will solve
Yet about the Zyloric of X.O. suppressor factor, it can accumulate a kind of meta-bolites oxipurinol (oxypurinol) in vivo, and has reported its spinoff such as fash, renal failure, hepatitis etc., therefore, and its always not wieldy medicament.In addition, heavily absorb (uricosuric Excretion) inhibiting benzbromarone about having uric acid, reported its severe side effect such as fulminant hepatitis, and can cause calculus.Therefore, need suitable conditional use, and its always not wieldy medicament.On the other hand, the clinical benefit of describing among the references 1-4 with the inhibiting antihyperuricemic Remedies of X.O. is still uncertain.As if the biaryl compound of describing in the references 5 or the pharmacological action of diaryl ether compound than a little less than the existing product.Most of therapeutical agents in the present technique field have been sold many decades, but select for broadening treatment, still need new therapeutical agent at medical field.
Therefore, the purpose of this invention is to provide compounds, and contain its pharmaceutical composition as activeconstituents with X.O. restraining effect and uricosuric Excretion.
The method of dealing with problems
The inventor is through studying addressing the above problem in earnest, and found that finally certain nitrogen-containing heterocycle compound with ad hoc structure has X.O. restraining effect and uricosuric Excretion, therefore constituted basis of the present invention.
That is, the present invention relates to:
By the nitrogen-containing heterocycle compound of following general formula (I) expression, or its pharmacy acceptable salt:
Y wherein 1Expression N or C (R 4); Y 2Expression N or C (R 5);
R 4And R 5Expression can have the alkyl of halogen atom, Wasserstoffatoms, halogen atom, cyanic acid, or alkoxyl group independently;
R 1And R 2In one the expression haloalkyl, cyanic acid, formamyl, or halogen atom;
R 1And R 2In another the expression aryl, it can have the substituting group that is selected from alkyl, haloalkyl, alkoxyl group and halogen atom, the some of them substituting group can form ring; Alkoxyl group; Or being selected from the heterocyclic group of thienyl, thiazolyl or pyrryl, it can be replaced by alkyl or halogen atom; With
R 3Expression 5-tetrazyl or carboxyl; And condition is to work as Y 2Expression CR 5The time, Y 2Can with R 2Form phenyl ring or pyridine ring together, it can have haloalkyl, halogen atom, cyanic acid or alkoxyl group as substituting group, and some adjacent substituting groups on ring can form ring;
By following general formula (I-A) or (I-B) as above [1] described nitrogen-containing heterocycle compound of expression, or its pharmacy acceptable salt:
R wherein 4aAnd R 5aRepresent Wasserstoffatoms or alkyl independently;
R 1aAnd R 2aIn one the expression haloalkyl, cyanic acid or halogen atom;
R 1aAnd R 2aIn another the expression aryl, it can have the substituting group that is selected from alkyl, haloalkyl, alkoxyl group and halogen atom, the some of them substituting group can form ring; Alkoxyl group; Or being selected from the heterocyclic group of thienyl, thiazolyl or pyrryl, it can be replaced by alkyl or halogen atom; With
R 3Expression 5-tetrazyl or carboxyl;
As above [2] described nitrogen-containing heterocycle compound or its pharmacy acceptable salt, wherein R 1aExpression cyanic acid;
As above [3] described nitrogen-containing heterocycle compound or its pharmacy acceptable salt, wherein R 2aThe expression aryl, it can have the substituting group that is selected from alkyl, haloalkyl, alkoxyl group and halogen atom, and the some of them substituting group can form ring; Alkoxyl group; Or thienyl, it can be replaced by alkyl or halogen atom;
As above each described nitrogen-containing heterocycle compound or its pharmacy acceptable salt, the wherein R of [2] to [4] 3The expression carboxyl;
By as above [1] described nitrogen-containing heterocycle compound of following general formula (I-C) expression, or its pharmacy acceptable salt:
Figure S2006800373585D00041
Y wherein 1CExpression N or C (R 4C); Y 3Expression N or C (R 9); R 4CAnd R 9Represent alkyl, haloalkyl, Wasserstoffatoms, halogen atom, cyanic acid or alkoxyl group independently;
R 1CExpression cyanic acid or formamyl;
R 6, R 7And R 8Represent alkyl, haloalkyl, Wasserstoffatoms, halogen atom, cyanic acid or alkoxyl group independently; Or R 6, R 7And R 8Any can form ring with adjacent substituting group; With
R 3Expression 5-tetrazyl or carboxyl;
As above [6] described nitrogen-containing heterocycle compound, or its pharmacy acceptable salt, wherein R 1CExpression cyanic acid;
As above [6] or [7] described nitrogen-containing heterocycle compound, or its pharmacy acceptable salt, wherein R 3The expression carboxyl;
Pharmaceutical composition comprises as above in [1] to [8] each described nitrogen-containing heterocycle compound or its pharmacy acceptable salt as activeconstituents;
As above [9] described pharmaceutical composition, it is an xanthine oxidase inhibitor;
As above [9] or [10] described pharmaceutical composition, it is the uricosuric eccritic;
As above each described pharmaceutical composition in [9] to [11], it is the medicament that is used to treat gout or hyperuricemia;
As above [9] described pharmaceutical composition, it is the medicament that is used to treat ischemia-reperfusion illness, inflammatory diseases, mellitus, cancer, arteriosclerosis or sacred disease or the like.
In addition, another kind of pharmaceutical composition of the present invention is characterized as the nitrogen-containing heterocycle compound that comprises the invention described above or its pharmacy acceptable salt as activeconstituents.
The definition of the substituting group that uses in this specification sheets etc. is following.Term " aryl " is meant phenyl, naphthyl, xenyl etc.Term " alkyl " can be straight chain, side chain or naphthenic base, and carbon atom number is not limited to but preferred 1-12.Moieties in " alkoxyl group " can be straight chain, side chain or naphthenic base, and carbon atom number is not limited to but preferred 1-12 is similar to abovementioned alkyl.
Term " halogen atom " is meant fluorine atom, chlorine atom, bromine atoms or iodine atom.Term " haloalkyl " is meant that abovementioned alkyl is replaced by the halogen atom of one or more (preferred 1-3) as above definition.Having under the situation of two or more halogen atoms, they can be different.
The invention effect
Nitrogen-containing heterocycle compound of the present invention or its pharmacy acceptable salt are the compound with X.O. restraining effect and uricosuric Excretion.Include these compounds and can be expected to as medicament, be used to treat gout or hyperuricemia and be used to treat various diseases such as ischemia-reperfusion illness, inflammatory diseases, mellitus, cancer, arteriosclerosis, sacred disease etc. as the pharmaceutical composition of the present invention of activeconstituents.
Optimum implementation of the present invention
General formula (I-A) or (I-B) under the situation of the nitrogen-containing heterocycle compound of expression on the nitrogen-containing heterocycle compound by general formula of the present invention (I) expression is, R 1And R 2In one be preferably cyanic acid and R 1And R 2In another is preferably aryl or alkoxyl group or thienyl, said aryl can have the substituting group that is selected from alkyl, haloalkyl, alkoxyl group and halogen atom, the some of them substituting group can form ring, said thienyl can be replaced by alkyl or halogen atom; And R 1Cyanic acid more preferably.As above-mentioned aryl, more preferably phenyl.As R 3, preferred carboxyl.
At the nitrogen-containing heterocycle compound by general formula of the present invention (I) expression is under the situation by the nitrogen-containing heterocycle compound of top general formula (I-C) expression, R 1CBe preferably cyanic acid.Preferred Y 1CBe C (R 4C) while Y 3Be C (R 9), R wherein 4CAnd R 9Be haloalkyl, Wasserstoffatoms, cyanic acid or alkoxyl group independently.As R 3, preferred carboxyl.
In nitrogen-containing heterocycle compound of the present invention; Pharmacy acceptable salt includes but not limited to, for example with the salt of following acid: hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, acetate, propionic acid, succsinic acid, oxyacetic acid, lactic acid, oxysuccinic acid, oxalic acid, tartrate, Hydrocerol A, toxilic acid, fumaric acid, methylsulfonic acid, Phenylsulfonic acid, tosic acid, xitix or the like.This type of salt can be hydrate, solvolyte etc.
Being characterized as of pharmaceutical composition of the present invention comprises nitrogen-containing heterocycle compound or its pharmacy acceptable salt as activeconstituents.Pharmaceutical composition of the present invention is suitable as xanthine oxidase inhibitor and/or uricosuric eccritic, and is used to treat gout or hyperuricemia.
In addition; Owing to producing relevant enzyme, XOD conduct and active oxygen receive publicity; Therefore pharmaceutical composition of the present invention is expected to produce as treatment and active oxygen the medicament of relevant disease, said disease such as ischemia reperfusion injury, inflammatory diseases, mellitus, cancer, arteriosclerosis, sacred disease etc.
In pharmaceutical composition of the present invention, restriction can not chosen any formulation of use wantonly.For example, oral administration form such as tablet, capsule, particle, fine particle, pulvis or liquid can illustrationally be arranged, or administered parenterally form such as injection, topical product or suppository, they can be prepared with ordinary method.
When using pharmaceutical composition of the present invention as therapeutical agent; Be used for gout or hyperuricemia; Or when being used for disease such as ischemia reperfusion injury, inflammatory diseases, mellitus, cancer, arteriosclerosis, sacred disease; Roughly within the scope of 1mg to 1g every day, this depends on each patient's age, sex, body weight and symptom degree to its using dosage, and per daily dose can be divided into several dosage for the adult.
The present invention further specifies through following embodiment.When explaining embodiment, use working title like " XO-TT53 ".
Embodiment 1
1. pyrazole derivatives is synthetic
Methyl phenyl ketone and the benzoic condensation reaction of 4-hydrazine through as raw material prepare hydrazone XO-TT462.Then, after XO-TT462 is converted into methyl esters, prepare XO-TT466 through Vilsmeier reaction cyclisation and formylation.At last, through then ester hydrolysis after the cyaniding, through 5 steps (following synthetic route), the total recovery with 17% prepares ultimate aim XO-TT469.
Figure S2006800373585D00071
Synthesized the compound of the carboxylic acid of XO-TT469 wherein by the tetrazol group conversion.Synthetic synthetic identical with top XO-TT466 basically.Yet, in the end in the cyaniding of XO-TT472, need not protect tetrazol group to react, can prepare XO-TT473 (following synthetic route) with low yield.
Figure S2006800373585D00072
Synthesized the compound that wherein methyl is introduced into the 5-position of XO-TT469 pyrazoles ring.Pyrazoles XO-TT485 is through 1-phenyl-1, the condensation reaction of 3-dimethyl diketone and hydrazine and preparing.Introduce 4-phenyl carboxylic acid (following synthetic route).
XO-TT486A is carried out formylation, obtain XO-TT499, and ultimate aim XO-TT507 can be through two other step preparation (following synthetic route).
Figure S2006800373585D00082
Synthesized the verivate that the terminal benzene of XO-TT469 wherein is converted into thiophene.At first, XO-TT500 prepares through the condensation reaction with the ethyl esterification of 2-acetyl thiophene and 4-hydrazine phenylformic acid.Ultimate aim XO-TT508 is with ordinary method preparation (following synthetic route).
Figure S2006800373585D00083
2.XO-TT469-the simplification of type compound method
At 2mol/L hydrochloric acid: under the condition of ethanol=1: 5, the condensation reaction through 2 '-chloro-acetophenone and 4-phenyl carboxylic acid prepares target compound carboxylic acid hydrazone XO-TT520.Need not protect carboxylic acid to carry out the Vilsmeier reaction.Its result can prepare and wherein forms pyrazoles ring and formylated XO-TT522.Ultimate aim XO-TT524 can be through cyaniding preparation (following synthetic route).
Objective carboxylic acid hydrazone XO-TT534 can have only ethanol to prepare as reacting under the solvent through making 4 '-methyl acetophenone.Ultimate aim XO-TT537 is with ordinary method preparation (following synthetic route) then.
Figure S2006800373585D00092
Above-mentioned synthetic 1 further explain below.
XO-TT-462
To methyl phenyl ketone (1.00g adds acetate (20mL) and water (2mL) in 8.32mmol), and to this stirred mixture adding 4-hydrazine phenylformic acid (1.27g, 8.32mmol).The mixture that obtains was stirred 21 hours down at 100 ℃.Add entry (200mL) to this reaction mixture, filter and collect through the precipitated solid that stirs the mixture, and dry under 80 ℃ under vacuum, obtain XO-TT462, be brown solid (900mg, 43% yield).
XO-TT463
(800mg 3.15mmol) is dissolved in the methyl alcohol (100mL), and adds the vitriol oil (1mL) to this solution, and mixture heating up was refluxed 30 hours with XO-TT462.Add entry to this reaction mixture, mixture is used ethyl acetate extraction.Organic layer is used anhydrous sodium sulfate drying, evaporating solvent.Resistates is through purification by silica gel column chromatography (hexane: ETHYLE ACETATE=5: 1-3: 1), obtain XO-TT463, be light yellow solid (465mg, 55% yield).
XO-TT466
The mixture of POCl3 (0.400mL) and N (3mL) was stirred 30 minutes down in 0 ℃ under nitrogen atmosphere.(460mg 1.72mmol), at room temperature stirred this mixture 12 hours to add XO-TT463 to this reaction mixture.Add entry (200mL) to this reaction mixture, filter and collect through the precipitated solid that stirs the mixture, and dry under 80 ℃ under vacuum, obtain XO-TT466, be light yellow solid (456mg, 87% yield).
XO-TT468
To XO-TT466 (400mg, add in 1.31mmol) formic acid (5.0mL), sodium formiate (177mg, 2.61mmol) and oxammonium hydrochloride (109mg, 1.57mmol), and with this mixture reflux 45 minutes under nitrogen atmosphere.Add entry (150mL) to this reaction mixture, mixture is stirred, and extract with ETHYLE ACETATE (200mL).Organic layer is used anhydrous sodium sulfate drying, under reduced pressure removes and desolvates.Resistates is through purification by silica gel column chromatography (hexane: ETHYLE ACETATE=5: 1-3: 1), obtain XO-TT468, be light yellow solid (338mg, 85% yield).
XO-TT469
With XO-TT468 (330mg 1.09mmol) is dissolved in 1,4-diox (20mL), and in this solution, add yellow soda ash (577mg, 5.45mmol) and water (5mL).This mixture is stirred down at 80 ℃.In reaction mixture, add entry (150mL), 2mol/L hydrochloric acid (30mL), and stir this mixture.The solid of filtration collecting precipitation is also dry under vacuum, obtains XO-TT469, is white solid (306mg, 97% yield).
XO-TT485
With 1-phenyl-1, (2.00g 12.3mmol) is dissolved in the ethanol 3-dimethyl diketone, and (1.80mL 37.0mmol), and stirs this mixture 3 hours down at 80 ℃ to add hydrazine monohydrate to this solution.Under reduced pressure the ethanol of reaction soln is removed after about 80%, added entry (200mL) to resistates.Filter the solid of collecting precipitation, and dry under 80 ℃ under vacuum, obtain XO-TT485, be white solid (1.88g, 97% yield).
XO-TT486A
With XO-TT485 (300mg 1.90mmol) is dissolved in the methyl-sulphoxide (10mL), and to this solution add 40% Potassium monofluoride-aluminum oxide (600mg), 4-fluorophenyl carbamate (492mL, 3.80mmol) with 18-hat-6 (100mg, 0.380mmol).This mixture was stirred 2 days down at 120 ℃.Add entry to this reaction mixture, mixture is used ethyl acetate extraction.Resistates is through purification by silica gel column chromatography (hexane: ETHYLE ACETATE=10: 1-5: 1), obtain XO-TT486A, be white solid (64.9mg, 12% yield).
XO-TT500
(1.00g 7.93mmol) is dissolved in the ethanol (30mL), and (1.21g is 7.93mmol) with 5mol/L hydrochloric acid (2mL) to add 4-hydrazine phenylformic acid to this solution with the 2-acetyl thiophene.This mixture was stirred 23 hours down at 100 ℃.Add entry (200mL) to this reaction mixture, mixture is with ethyl acetate extraction (200mL).Under reduced pressure remove and desolvate, resistates is through purification by silica gel column chromatography (hexane: ETHYLE ACETATE=4: 1), obtain XO-TT500, be light yellow solid (781mg, 34% productive rate).
Embodiment 2
1.XO-B327 synthetic
After making alpha-cyano styracin and tolysulfonyl ylmethyl isocyanide prepared in reaction azole cpds XO-B315 (88% yield), the linked reaction through 4-fluorophenyl carbamate and XO-B315 prepares XO-B321 (41% yield).Then, ultimate aim XO-B327 synthesizes (94% yield, following synthetic route) through the ester hydrolysis.
Figure DEST_PATH_G200680037358501D00011
2.XO-B366 synthetic
Through diazotization Tolylamine (toluizine) and make it and ethyl benzoylacetate reacts and prepares (quantitative yield) behind the XO-B348, use cupric iodide (I) preparation triazole compounds XO-B351 (89% yield).Then, XO-B358 prepares through ethoxycarbonyl being converted into acid amides (92% yield) and being translated into cyanic acid (88% yield) through dehydration.Then, the mixture of bromide compounds XO-B362 (5% yield) and XO-B362-2 (8% yield) prepares through the bromination of methyl, and ultimate aim XO-B366 is through direct hydrolysis synthetic (19% yield, following synthetic route).
Figure DEST_PATH_G200680037358501D00012
Figure S2006800373585D00131
Above-mentioned synthetic further explain below.
1) XO-B315's is synthetic
Figure S2006800373585D00132
(2.96g 45mmol) is dissolved in the methyl alcohol (30mL), and this solution is cooled off in ice with Pottasium Hydroxide.(1.73g 10mmol), and stirs this mixture 30 minutes down ice-cooled to add alpha-cyano styracin to this solution.At 5 ℃ down or under the lower temperature, to this reaction mixture drip tolylsulfonyl ylmethyl isocyanide (2.05g, the 10.5mmol) solution in methylene dichloride (15mL), 17 minutes times spent, and with this mixture ice-cooled restir down 1 hour.Add entry (10mL) to this reaction mixture, dissolving insoluble material, and mixture is adjusted to pH8 through adding 10% hydrochloric acid.Under reduced pressure remove organic solvent, and in resistates, add entry (20mL), this mixture was at room temperature stirred 30 minutes.Filter and collect the solid that forms,, obtain XO-TT315, be light brown tabular crystal (1.48g, 88.1% yield) with water washing and under reduced pressure dry under 60 ℃.
Embodiment 3
1. 3-cyanoindole verivate synthetic that has terminal carboxylic acid
Basic compound method with verivate of terminal carboxylic acid is presented in the following synthetic route.
Figure S2006800373585D00141
Target compound prepares with following order through 4 steps altogether: (1) uses POCl3 to make the 3-position formylation (Vilsmeier method) of corresponding indoles in the presence of N, and (2) are in sodium formiate and formic acid; Through carrying out cyaniding with the dehydration reaction of azanol; (3) in methyl-sulphoxide, in the presence of carrying alumina Potassium monofluoride and 18-hat-6-ether, with the coupling of 4-ethyl fluoro benzoate; Then, the Lithium Hydroxide MonoHydrate hydrolysis is used in (4).The result is presented in the following table 1.In addition, XO-CH146 (R=H) uses the 3-cyanoindole preparation of buying from the 3rd step.
Figure S2006800373585D00142
2.XO-CH150 synthetic
XO-CH145 is to be similar to the mode in the 3rd step of top 1, and the coupling through indole-3-formaldehyde and 4-fluorine benzonitrile prepares.XO-CH147 prepares through using sodiumazide that XO-CH145 is converted into terazole derivatives, then uses azanol to carry out cyaniding, obtains XO-CH150 (following synthetic route).
Figure S2006800373585D00151
3.XO-CH151 synthetic
XO-CH151 uses the ammoniacal liquor amidation through the Indole-3-Carboxylic Acid is converted into acyl chlorides, is converted into tetrazolium with the mode that is similar to XO-CH150 then and prepares (following synthetic route).
Figure S2006800373585D00152
Above-mentioned synthetic 1-3 explanation in further detail below.
1.XO-CH164 synthetic
XO-CH155
Under argon atmospher, (1.04g 7.93mmol) is dissolved in the N (10mL), and under ice-cooled, drips POCl3 (2mL) to this solution, and the mixture that obtains was at room temperature stirred 1.5 hours with the 5-skatole.Under ice-cooled,, this mixture heating up was refluxed 1 hour to this reaction mixture dropping sodium aqueous solution (5g/15mL).Down reaction mixture is adjusted to pH 2-3 with concentrated hydrochloric acid ice-cooled, solid collected by filtration then, and under reduced pressure in 60 ℃ dry down, obtain XO-CH155, be lightpink solid (1.13g, 90% yield).
XO-CH158
With XO-CH155 (0.600g 3.77mmol) is dissolved in the formic acid (6mL), and to this solution add oxammonium hydrochloride (0.31g, 4.5mmol) with sodium formiate (0.47g, 6.9mmol), with this mixture heating up backflow 1 hour.Add entry at ice-cooled downhill reaction mixture, stirred this mixture 1.5 hours.Solid collected by filtration is also under reduced pressure dry under 60 ℃, obtains XO-CH158, is purple solid (0.397g, 67% yield).
XO-CH161
With XO-CH158 (0.387mg 2.48mmol) is dissolved in the methyl-sulphoxide (20mL), and to this solution add the 4-ethyl fluoro benzoate (0.36mL, 2.5mmol), 40% carrying alumina Potassium monofluoride (0.38g) and 18-hat-6-ether (0.07g, 0.3mmol).This mixture is also filtered 120 ℃ of following stirred overnight.Add entry to filtrating, mixture is used ethyl acetate extraction.Organic layer water (3 times) and brine wash, anhydrous magnesium sulfate drying filters.Concentrated filtrate and drying under reduced pressure.Resistates obtains XO-CH161 through purification by silica gel column chromatography (silica gel 50g, ethyl acetate/hexane=1/6), is white solid (0.186g, 25% yield).In addition, the level that obtains containing high polar compound through column chromatography is divided and is used the ethyl acetate/hexane recrystallization, obtains XO-CH161 in addition, is white solid (0.165g, 22% yield).
XO-CH164
(0.186g 0.611mmol) is dissolved in the THF (10mL), and adds lithium hydroxide monohydrate (0.042g, 0.99mmol) solution in water (5mL) to this solution with XO-CH161.This mixture was at room temperature stirred 6 hours.In ice-water bath, add entry and be adjusted to pH 1 with 2mol/L hydrochloric acid to this reaction mixture.Solid collected by filtration, and under reduced pressure dry under 60 ℃, obtain XO-CH164, be white solid (0.154g, 91% yield).
2.XO-CH146 synthetic
XO-CH144
XO-CH144 prepares with the mode that is similar to XO-CH161, is light brown solid (0.123g, 60% yield).
XO-CH146
XO-CH146 prepares with the mode that is similar to XO-CH164, is white solid (0.082g, 81% yield).
3.XO-CH160 synthetic
XO-CH154
XO-CH154 prepares with the mode that is similar to XO-CH155, is light yellow solid (2.34g, 97% yield).
XO-CH156
XO-CH156 prepares with the mode that is similar to XO-CH158, is green-gray solid (0.96g).
XO-CH159
XO-CH159 prepares with the mode that is similar to XO-CH161, is white crystal (0.57g, 32% yield (in 2 steps)).
XO-CH160
XO-CH160 prepares with the mode that is similar to XO-CH164, is white solid (0.453g, 85% yield).
4.XO-CH168 synthetic
XO-CH157
XO-CH157 prepares with the mode that is similar to XO-CH155, is light yellow solid (2.30g, 95% yield).
XO-CH163
XO-CH163 prepares with the mode that is similar to XO-CH158, is green-brown solid (0.354g, 71% yield).
XO-CH167
XO-CH167 prepares with the mode that is similar to XO-CH161, is light yellow solid (0.373g, 55% yield).
XO-CH168
XO-CH168 prepares with the mode that is similar to XO-CH164, is light yellow solid (0.235g, 69% yield).
5.XO-CH150 synthetic
XO-CH145
XO-CH145 prepares with the mode that is similar to XO-CH161, is light brown crystal (0.608g, 72% yield).
XO-CH147
With XO-CH145 (0.200g 0.811mmol) is dissolved in the 1-Methyl-2-Pyrrolidone (6mL), then to this solution add sodiumazide (0.17g, 2.6mmol) and Triethylammonium chloride (0.23g, 1.7mmol).This mixture was stirred 14 hours down at 120 ℃.Add entry to reaction mixture, then this mixture hydrochloric acid with 2mol/L in ice-water bath is adjusted to pH 3, and stirred 30 minutes.Solid collected by filtration and under 60 ℃ in the following drying of decompression, obtain XO-CH147, be brown solid (0.248g, quantitative yield).
XO-CH150
XO-CH150 prepares with the mode that is similar to XO-CH158, is red-brown solid (0.147g, 69% yield).
6.XO-CH151 synthetic
XO-CH148
With the Indole-3-Carboxylic Acid (0.494g 3.07mmol) is suspended in the methylene dichloride (10mL), and to this suspension-s add THIONYL CHLORIDE 97 (0.27mL, 3.7mmol) and acetonitrile (5mL).This mixture was stirred 1 hour down at 60 ℃, to this reaction mixture add again THIONYL CHLORIDE 97 (0.27mL, 3.7mmol).This mixture was stirred 1 hour.Behind the solvent evaporate to dryness with reaction mixture, resistates is dissolved in the acetonitrile (5mL).In ice-water bath, add 28% ammonia soln (2mL), and this mixture was stirred 30 minutes to this solution.Add entry to this reaction mixture, and mixture is used ethyl acetate extraction.Organic layer water (twice) and brine wash, and use anhydrous sodium sulfate drying, filter.Concentrated filtrate and drying under reduced pressure obtain XO-CH148, are light yellow solid (0.252g, 51% yield).
XO-CH149
XO-CH149 prepares with the mode that is similar to XO-CH161, is pale yellow crystals (0.102g, 61% yield).
XO-CH151
XO-CH151 prepares with the mode that is similar to XO-CH147, is light yellow solid (0.018g, 19% yield).
Embodiment 4
1. indole derivatives is synthetic
1) 3-cyanoindole verivate is synthetic
9 target compounds prepare according to following order through 4 steps altogether: the 3-position formylation (Vilsmeier method) of POCl3 with corresponding indoles used in (1) in the presence of N; (2) in sodium formiate and formic acid; Dehydration reaction through with azanol is carried out cyaniding, and coupling is carried out with the 4-ethyl fluoro benzoate in (3) in methyl-sulphoxide in the presence of carrying alumina Potassium monofluoride and 18-hat-6-ether; Then, (4) are with Lithium Hydroxide MonoHydrate hydrolysis (following table 2).In addition, XO-CH172 and XO-CH183 (R is respectively 2-methyl or 5-methoxyl group) use the corresponding aldehyde of buying to prepare from step 2.
Figure S2006800373585D00211
2) XO-CH211's is synthetic
Target compound (XO-CH210) prepares through the XO-CH208 of cyaniding by formylation and linked reaction preparation.Then, hydrolysis XO-CH210 obtains target compound (XO-CH211) (following synthetic route).
2.7-7-azaindole derivatives is synthetic
1) XO-KT10's is synthetic
XO-KT2 prepares through the linked reaction with the 4-ethyl fluoro benzoate.XO-KT5-2 prepares with XO-KT2 through using POCl3.Subsequently, with the ordinary method cyaniding, then hydrolysis obtains XO-KT10 (following synthetic route) with the aldehyde of XO-KT5-2.
Figure S2006800373585D00222
2) XO-KT16's is synthetic
With reference to the compound method of describing in top (1), the 5-br-derivatives of XO-KT10 is from 5-bromo-7-azaindole preparation (following synthetic route).
Figure S2006800373585D00231
3) XO-KT18's is synthetic
Similarly, the 6-chlorine derivative of XO-KT10 is from 6-chloro-7-azaindole preparation (following synthetic route).
Figure S2006800373585D00232
4) XO-KT20's is synthetic
5-cyano derivative (XO-KT20) is through using zinc cyanide to the XO-KT14 cyaniding, and then hydrolysis prepares (following synthetic route).
Figure S2006800373585D00241
3. indazole derivatives is synthetic
Iodine is caused the 3-position (following synthetic route) of indazole ring.Target compound XO-KT30 is converted into cyanic acid through using zinc cyanide with iodine, then through the ordinary method coupling, prepares through hydrolysis at last.
Figure S2006800373585D00242
Above-mentioned synthetic 1-3 further explain below.
1) XO-CH200's is synthetic
XO-CH180
Under argon atmospher, (1.004g 7.62mmol) is dissolved in the N (10mL), and under ice-cooled, adds POCl3 (2mL) to this solution with the 6-skatole.This mixture was at room temperature stirred 1.5 hours.Under ice-cooled, to the reaction mixture dropping sodium aqueous solution (5g/15mL).Mixture heating up was refluxed 1.5 hours.Add entry to reaction mixture down ice-cooled, this mixture is adjusted to pH 3 with concentrated hydrochloric acid.Solid collected by filtration, and under reduced pressure dry under 60 ℃, obtain XO-CH180, be light brown solid (1.14g, 94% yield).
XO-CH186
With XO-CH180 (1.14g 7.16mmol) is dissolved in the formic acid (11mL), to this solution add oxammonium hydrochloride (0.63g, 9.1mmol) and sodium formiate (0.90g, 13mmol).Mixture heating up was refluxed 1 hour.Add entry to reaction mixture down ice-cooled, and this mixture is stirred a little while.Solid collected by filtration, and under reduced pressure dry under 60 ℃, obtain XO-CH186, be red-black solid (0.85g, 76% yield).
XO-CH192
With XO-CH186 (0.502mg 3.21mmol) is dissolved in the methyl-sulphoxide (25mL), and to this solution add the 4-ethyl fluoro benzoate (0.47mL, 3.2mmol), 40% carrying alumina Potassium monofluoride (0.48g) and 18-hat-6-ether (0.10g, 0.38mmol).This mixture was stirred 16 hours down at 120 ℃.Filter this reaction mixture, water is added in the filtrating.Mixture is with ethyl acetate extraction (twice).Organic layer water (twice) and brine wash, anhydrous magnesium sulfate drying, and filter.Concentrated filtrate and drying under reduced pressure.Resistates obtains XO-CH192 through purification by silica gel column chromatography (silica gel 50g, chloroform), is light orange solid (0.589g, 60% yield).
XO-CH200
(0.298g 0.978mmol) is dissolved in the THF, and (0.0702g is 1.67mmol) with the alcoholic acid aqueous solution to add lithium hydroxide monohydrate to this solution with XO-CH192.This mixture was at room temperature stirred 5 hours.In ice-water bath, add entry to this reaction mixture, with 2mol/L hydrochloric acid this mixture is adjusted to pH 1.Solid collected by filtration, and under reduced pressure dry under 60 ℃, obtain XO-CH200, be lightpink solid (0.260g, 96% yield).
2) XO-CH172's is synthetic
XO-CH169
XO-CH169 prepares with the mode that is similar to XO-CH186, is black-brown solid (1.45g, 74% yield).
XO-CH170
XO-CH170 prepares with the mode that is similar to XO-CH192, is light yellow solid.
XO-CH172
XO-CH172 prepares with the mode that is similar to XO-CH200, is light yellow solid (0.107g, 74% yield).
3) XO-CH201's is synthetic
XO-CH184
XO-CH184 prepares with the mode that is similar to XO-CH180, is light orange solid (1.20g, quantitative yield).
XO-CH189
XO-CH189 prepares with the mode that is similar to XO-CH186, is green-brown solid (0.805g, 75% yield).
XO-CH195
XO-CH195 prepares with the mode that is similar to XO-CH192, is pale yellow-green solid (0.304g, 32% yield).
XO-CH201
XO-CH201 prepares with the mode that is similar to XO-CH200, is light yellow solid (0.261g, 96% yield).
4) XO-CH183's is synthetic
XO-CH171
XO-CH171 prepares with the mode that is similar to XO-CH186, is black-brown solid (0.790g, 69% yield).
XO-CH173
XO-CH173 prepares with the mode that is similar to XO-CH192, is white solid (0.689g, 75% yield).
XO-CH183
XO-CH183 prepares with the mode that is similar to XO-CH200, is white crystal (0.496g, 79% yield).
5) XO-CH199's is synthetic
XO-CH178
XO-CH178 prepares with the mode that is similar to XO-CH180, is light brown solid (1.22g, 92% yield).
XO-CH179
XO-CH179 prepares with the mode that is similar to XO-CH186, is black-brown solid (1.05g, 87% yield).
XO-CH190
XO-CH190 prepares with the mode that is similar to XO-CH192, is white solid (0.468g, 52% yield).
XO-CH199
XO-CH199 prepares with the mode that is similar to XO-CH200, is white solid (0.234g, 86% yield).
6) XO-CH207's is synthetic
XO-CH187
XO-CH187 prepares with the mode that is similar to XO-CH180, is brown solid (1.22g, 92% yield).
XO-CH193
XO-CH193 prepares with the mode that is similar to XO-CH186, is green-brown solid (0.413g, 77% yield).
XO-CH203
XO-CH203 prepares with the mode that is similar to XO-CH192, is light yellow solid (0.410g, 53% yield).
XO-CH207
XO-CH207 prepares with the mode that is similar to XO-CH200, is light yellow solid (0.346g, 92% yield).
7) XO-CH209's is synthetic
XO-CH182
XO-CH182 prepares with the mode that is similar to XO-CH180, is light yellow solid (1.20g, 99% yield).
XO-CH188
XO-CH188 prepares with the mode that is similar to XO-CH186, is light green solid (1.03g, 88% yield).
XO-CH194
XO-CH194 prepares with the mode that is similar to XO-CH192, is light yellow solid (0.810g, 89% yield).
XO-CH209
XO-CH209 prepares with the mode that is similar to XO-CH200, is white crystal (0.206g, 74% yield).
8) XO-CH206's is synthetic
XO-CH185
XO-CH185 prepares with the mode that is similar to XO-CH180, is light yellow solid (0.268g, 92% yield).
XO-CH191
XO-CH191 prepares with the mode that is similar to XO-CH186, is light blue-green solid (0.213g, 82% yield).
XO-CH202
XO-CH202 prepares with the mode that is similar to XO-CH192, is light yellow solid (0.191g, 53% yield).
XO-CH206
XO-CH206 prepares with the mode that is similar to XO-CH200, is light yellow solid (0.155g, 88% yield).
9) XO-CH205's is synthetic
XO-CH175
XO-CH175 prepares with the mode that is similar to XO-CH180, is yellow solid (1.15g, 95% yield).
XO-CH176
XO-CH176 prepares with the mode that is similar to XO-CH186, is chocolate solid (0.762g, 78% yield).
XO-CH196
XO-CH196 prepares with the mode that is similar to XO-CH192, is light yellow solid (0.095g, 10% yield).
XO-CH205
XO-CH205 prepares with the mode that is similar to XO-CH200, is white solid (0.075g, 87% yield).
10) XO-CH211's is synthetic
XO-CH174
XO-CH174 prepares with the mode that is similar to XO-CH180, is lightpink solid (0.549g, 46% yield).
XO-CH208
XO-CH208 prepares with the mode that is similar to XO-CH192, is yellow solid (0.598g, 59% yield).
XO-CH210
XO-CH210 prepares with the mode that is similar to XO-CH186, is light yellow solid (0.162g, 27% yield).
XO-CH211
XO-CH211 prepares with the mode that is similar to XO-CH200, is light yellow solid (0.130g, 88% yield).
11) XO-KT10's is synthetic
XO-KT2
XO-KT2 prepares (1.32g, 50% yield) with the mode that is similar to XO-CH192.
XO-KT5-2
(560mg 2.1mmol) is dissolved in the N (4.3mL), and in this solution, adds POCl3 (0.8mL) with XO-KT2.This mixture was at room temperature stirred 2 hours.After the reaction, add aqueous sodium hydroxide solution (2.7g/8mL), and this mixture heating up was refluxed 1 hour to this reaction mixture.After the reaction, this reaction mixture is cooled to room temperature, and with ETHYLE ACETATE that adds and water extraction.Organic layer is used brine wash, and uses anhydrous magnesium sulfate drying, under reduced pressure concentrated solvent.Resistates is through purification by silica gel column chromatography (methylene dichloride: methyl alcohol=5: 1), obtain XO-KT5-2 (374mg, 61% yield).
XO-KT9
XO-KT9 prepares (0.354g, 87% yield) with the mode that is similar to XO-CH186.
XO-KT10
(266mg 1mmol) is dissolved in the mixed solvent of methyl alcohol (4mL) and water (4mL), and adds sodium hydroxide (80mg) to this solution with XO-KT2.This mixture heating up was refluxed 0.5 hour.After the reaction, reaction mixture is cooled to room temperature, adds acetate (0.5mL) to this reaction mixture.Filter collecting precipitation, washing is also dry, obtains XO-KT6 (230mg, 97% yield).
12) XO-KT16's is synthetic
XO-KT3
XO-KT3 prepares (57% yield) with the mode that is similar to XO-CH192.
XO-KT7
(3.45g 10mmol) is dissolved in the N (30.5mL), and in this solution, adds POCl3 (3.8mL) with XO-KT3.This mixture was at room temperature stirred 72 hours.After the reaction, in this reaction mixture, add aqueous sodium hydroxide solution (12.9g/38mL) lentamente, add entry (200mL) then.Filter collecting precipitation, washing is also dry, obtains XO-KT7 (3.42g, 92% yield).
XO-KT14
XO-KT3 prepares (quantitative yield) with the mode that is similar to XO-CH186.
XO-KT16
XO-KT16 prepares (0.333g, 97% yield) with the mode that is similar to XO-CH200.
13) XO-KT18's is synthetic
XO-KT4
XO-KT4 prepares (77% yield) with the mode that is similar to XO-CH192.
XO-KT8
XO-KT8 prepares (74% yield) with the mode that is similar to XO-KT7.
XO-KT15
XO-KT15 prepares (99% yield) with the mode that is similar to XO-CH186.
XO-KT18
XO-KT18 prepares (95% yield) with the mode that is similar to XO-CH200.
14) XO-KT20's is synthetic
XO-KT19
Under argon atmospher, with XO-KT14 (0.370g, 1mmol) and zinc cyanide (0.235g; 2mmol) be dissolved in the N (12mL); And in this solution, add tetrakis triphenylphosphine palladium (0) (0.166g, 0.1mmol), and with this mixture 120 ℃ of following stirred overnight.After the reaction, this reaction mixture is cooled to room temperature, mixture is with ETHYLE ACETATE that adds and water extraction.Extract is used brine wash, uses anhydrous magnesium sulfate drying, and under reduced pressure concentrates.Resistates is recrystallization from the mixed solvent of ETHYLE ACETATE and hexane, obtains XO-KT19 (0.281g, 89%).
XO-KT20
XO-KT20 prepares (79% yield) with the mode that is similar to XO-CH200.
15) XO-KT30's is synthetic
XO-KT13
With indazole (1.18g 10mmol) is dissolved in the N (6mL), and in this solution, add iodine (2.8g, 11mmol) and Pottasium Hydroxide (2.8g 50mmol), makes under this mixture room temperature reaction 0.5 hour.After the reaction, reaction mixture is with ETHYLE ACETATE that adds and water extraction.Organic layer is used brine wash, and uses anhydrous magnesium sulfate drying, under reduced pressure concentrated solvent.Resistates is recrystallization from the mixed solvent of ETHYLE ACETATE and hexane, obtains XO-KT13 (1.55g, 64% yield).
XO-KT23
XO-KT23 prepares (41% yield) with the mode that is similar to XO-KT19.
XO-KT30
XO-KT24 prepares with the mode that is similar to XO-KT192, and XO-KT30 prepares (2 step yield 59%) with the mode that is similar to XO-CH200 then.
Embodiment 5
The all types of target verivate is synthetic according to following reaction synthetic route.The result of each synthesis step is shown in the following table 3.
Figure S2006800373585D00331
Figure S2006800373585D00341
Above-mentioned synthetic further explain below.
XO-TT538
With 4 '-methoxyacetophenone (1.00g 6.66mmol) is dissolved in the ethanol (20mL), and in this solution, add 4-hydrazine phenylformic acid (1.06g, 6.99mmol).This mixture was stirred 46 hours down at 100 ℃.Add entry (250mL) to this reaction mixture, mixture is with ethyl acetate extraction (200mL, twice).Organic layer is dry with no water sodium hydroxide, the vapourisation under reduced pressure solvent.Resistates obtains XO-TT538 from the acetone-water recrystallization, is light yellow solid (1.26g, 67% yield).
XO-TT539
The mixture of POCl3 (0.988mL) and N (10mL) was stirred 30 minutes down in 0 ℃ under nitrogen atmosphere.(1.00g 3.52mmol), at room temperature stirred this mixture 21 hours to add XO-TT538 to this reaction mixture.Add entry (500mL) to this reaction mixture.Filter and collect through the precipitated solid that stirs the mixture, and dry under 80 ℃ under vacuum, obtain XO-TT539, be white solid (646mg, 57% yield).
XO-TT544
To XO-TT539 (300mg, add in 0.932mmol) formic acid (10mL), sodium formiate (126mg, 1.86mmol) with oxammonium hydrochloride (77.8mg, 1.12mmol), with this mixture under nitrogen atmosphere in 80 ℃ of stirrings 32 hours down.Add entry (100mL) to this reaction mixture.Filter to collect through the precipitated solid that stirs the mixture, and from acetone-water recrystallization, obtain XO-TT544, be white solid (176mg, 59% yield).
Embodiment 6
1. the alpha-cyano ethyl cinnamate derivative is synthetic
Use aldehyde and ethyl cyanacetate to synthesize (following synthetic route) alpha-cyano ethyl cinnamate derivative through the Knoevenagel condensation as raw material.The result is shown in the following table 4.
Figure S2006800373585D00351
XO-B363 96.2％(4.53g)
XO-B364 93.1％(3.85g)
XO-B365 92.2％(4.26g)
XO-B367 94.9％(4.08g)
XO-B369 79.7％(3.45g)
XO-B370 73.3％(3.24g)
XO-B372 94.6％(3.86g)
XO-B374 91.5％(4.92g)
XO-B377 92.3％(4.46g)
XO-B378 86.8％(3.60g)
XO-B380 91.1％(2.25g)
XO-B383 91.8％(4.33g)
XO-B385 96.8％(4.47g)
XO-B387 91.7％(3.94g)
XO-B390 91.5％(4.92g)
XO-B419 69.8％(3.52g)
XO-B424 93.4％(4.09g)
XO-B427 91.6％(4.01g)
In addition, it is following to list in the structure of each compound title in the table 4.
Figure S2006800373585D00371
2.3-the cyanopyrrole verivate is synthetic
Through being reacted, alpha-cyano ethyl cinnamate derivative and tolylsulfonyl ylmethyl isocyanide prepare (following synthetic route) 3-cyanopyrrole verivate.After reaction mixture neutralizes in aftertreatment (work-up), the evaporation organic solvent.Filter and collect precipitated solid when adding entry.The optional recrystallization that carries out.Under the situation of XO-B376, after the extraction, solid comes purifying through column chromatography and recrystallization.The result is shown in the following table 5.
Figure S2006800373585D00372
XO-B368 91.5％(1.86g)
XO-B371 92.8％(1.62g)
XO-B373 99.5％(1.97g)
XO-B375 93.4％(1.70g)
XO-B376 78.3％(1.47g)
XO-B379 89.7％(1.69g)
XO-B381 94.3％(1.61g)
XO-B382 91.3％(2.15g)
XO-B384 83.8％(1.75g)
XO-B386 99.0％(1.72g)
XO-B388 96.1％(1.68g)
XO-B389 quant.(2.08g)
XO-B391 98.9％(1.96g)
XO-B396 quant.(1.86g)
XO-B398 quant.(2.44g)
XO-B425 quant.(2.28g)
XO-B430 95.4％(1.77g)
XO-B431 quant.(1.88g)
In addition, it is following to list in the structure of each the compound title in the table 5.
Figure S2006800373585D00391
3.4-(3-cyanic acid-1-pyrryl) oil of Niobe verivate is synthetic
4-(3-cyanic acid-1-pyrryl) oil of Niobe verivate synthesizes (following synthetic route) through the coupling of 3-cyanopyrrole verivate and 4-fluorophenyl carbamate.Reaction mixture with the s.t. of 1mol/L salt, is filtered the solid of collecting precipitation, and passes through recrystallization purifying.The result is shown in the table 6.
Figure S2006800373585D00401
Compound Yield
Compound Yield
?XO-B392 70.7％(1.43g)
?XO-B393 52.8％(971mg)
?XO-B394 71.9％(1.44g)
?XO-B395 57.7％(1.09g)
?XO-B395-1 7.1％(128mg)
?XO-B399 50.9％(9857mg)
?XO-B399-2 6.9％(128mg)
?XO-B400 62.4％(1.21g)
?XO-B402 60.3％(1.11g)
?XO-B404 71.0％(1.58g)
?XO-B406 70.4％(1.44g)
?XO-B408 63.9％(1.18g)
?XO-B409 67.0％(1.24g)
?XO-B411 65.1％(1.32g)
?XO-B413 73.9％(1.43g)
?XO-B415 62.1％(1.17g)
?XO-B416 52.1％(1.16g)
?XO-B429 66.6％(1.44g)
?XO-B432 70.4％(1.36g)
?XO-B433 72.9％(1.40g)
In addition, it is following to list in the structure of each compound title in the table 6.
Figure S2006800373585D00411
4.4-(3-cyanic acid-1-pyrryl) benzoic acid derivative is synthetic
Ester hydrolysis through 4-(3-cyanic acid-1-pyrryl) oil of Niobe verivate prepares (following synthetic route) ultimate aim 4-(3-cyanic acid-1-pyrryl) benzoic acid derivative.The result is shown in the following table 7.
Compound Yield
Compound Yield
XO-B397 92.2％(595mg)
XO-B401 96.2％(283mg)
XO-B403 93.8％(298mg)
XO-B395-1 97.6％(295mg)
XO-B399-2 99.8％(307mg)
XO-B407 92.4％(285mg)
XO-B410 97.5％(284mg)
XO-B412 95.3％(339mg)
XO-B414 95.3％(314mg)
XO-B418 97.8％(288mg)
XO-B420 98.3％(290mg)
XO-B421 98.2％(317mg)
XO-B422 98.2％(312mg)
XO-B423 95.8％(289mg)
XO-B428 93.0％(331mg)
XO-B434 98.2％(340mg)
XO-B436 94.8％(290mg)
XO-B438 93.9％(287mg)
In addition, it is following to list in the structure of each compound title in the table 7.
Figure S2006800373585D00431
5.XO-B440 synthetic
Through tolylsulfonyl ylmethyl isocyanide methylate synthesize XO-B435 (quantitative yield), and then, synthesize XO-B437 (71% yield) through the reaction that forms the pyrroles.Subsequently, through being hydrolyzed, prepare ultimate aim XO-B440 (2 step yields 42%, following synthetic route) with the coupling of 4-fluorophenyl carbamate and to the ester of gained XO-B439.
Figure S2006800373585D00441
Above-mentioned synthetic 1-5 further explain below.
1) XO-B363's is synthetic
Figure S2006800373585D00442
With the 2-chlorobenzaldehyde (2.81g, 20mmol) and ethyl cyanacetate (2.26g 20mmol) mixes with ethanol (30mL), and adds several piperidines to this mixture.This mixture was at room temperature stirred 7 hours.Concentrated reaction mixture under reduced pressure, resistates separates (130g, dichloromethane/hexane=1/1) through silica gel column chromatography, obtains XO-B363, is white needle-like crystals (4.53g, 96.24% yield).
2) XO-B368's is synthetic
Figure S2006800373585D00443
(2.36g 10mmol) is suspended in the ethanol (20mL), and this suspension-s is ice-cold with XO-B363.In this mixture, slowly add sodium ethylate ethanolic soln (21%wt, 4.5mL, 12.1mmol) after; Under 5 ℃ or lower temperature; Drip tolylsulfonyl ylmethyl isocyanide (2.05g, the 10.5mmol) solution in methylene dichloride (15mL), 16 minutes times spent.This mixture was stirred 30 minutes down ice-cooled.In reaction mixture, add entry (10mL) to dissolve insoluble material, add 10% hydrochloric acid this solution is adjusted to pH 8.Under reduced pressure remove organic solvent, (20mL) adds in the resistates with water.This mixture was at room temperature stirred 30 minutes.Filter the solid of collecting precipitation, with water washing and under reduced pressure dry down in 60 ℃.The crude product that obtains recrystallization from methylene dichloride-hexane obtains XO-B368, is light brown needle-like crystal (1.86g, 91.51% yield).
3) XO-B392's is synthetic
Figure S2006800373585D00451
(1.22g 6mmol) is dissolved in the N (15mL), and this solution is ice-cold with XO-B368.To this solution gradation add sodium hydride (55% oil solution, 315mg, 7.2mmol) after, add the 4-fluorophenyl carbamate (780 μ L, 6mmol).This mixture was stirred 2 hours down in 150 ℃ under argon atmospher.After the cooling, reaction mixture is poured in the refrigerative 1mol/L hydrochloric acid (45mL).Filter the solid of collecting precipitation, use water washing, and under reduced pressure dry down in 60 ℃.The crude product that obtains recrystallization from ETHYLE ACETATE obtains XO-B392, is light brown needle-like crystal (1.43g, 70.7% yield).
4) XO-B397's is synthetic
Figure S2006800373585D00452
With XO-B392 (637mg 2mmol) is dissolved in the diox (10mL) down in heating, and to this solution adding yellow soda ash (636mg, 6mmol) and water (1mL).Mixture added to diox (10mL) and water (3mL) in this reaction mixture after refluxing 14 hours.This mixture restir 72 hours.Concentrated reaction mixture under reduced pressure.In resistates, add entry (30mL), dissolving mixt under heating.Through adding the 2mol/L hydrochloric acid conditioning solution to pH 2.Filter the solid of collecting precipitation, with water washing and under reduced pressure dry down in 60 ℃.The crude product that obtains recrystallization from THF-water, and under reduced pressure dry under 60 ℃, obtain XO-B397, be white needle-like crystals (595mg, 92.2% yield).
5) XO-B435's is synthetic
Figure S2006800373585D00461
(2.93g 15mmol) is dissolved in the methylene dichloride (30mL), and this solution is cooled off down at 0 ℃ with tolylsulfonyl ylmethyl isocyanide.To this solution add benzyltriethylammoinium chloride (683mg, 3mmol), (1.85mL is 30mmol) with 30% aqueous sodium hydroxide solution (30mL) for methyl-iodide.This mixture was stirred 3 hours down in 0 ℃ under sealing.Add entry (150mL) to this reaction mixture, and this mixture extracts with methylene dichloride (75mL, twice).Organic layer is used dried over sodium sulfate, and under reduced pressure concentrates.Because residual benzyltriethylammoinium chloride is dissolved in resistates in the methylene dichloride (100mL), this solution with water (30mL, twice) washing.Organic layer obtains XO-B435 with dried over sodium sulfate and under reduced pressure concentrated, is brown oil (3.26g, quantitative yield).
Above-mentioned synthetic compound is carried out following pharmaceutical research.
1) XOD restraining effect
Carry out the XOD inhibition analysis at 100 μ mol/L concentration of substrate (ultimate density), 5mU/mL enzyme concn (ultimate density) with in as the The compounds of this invention of test compounds, The compounds of this invention with XOD (from buttermilk; Biozyme laboratories), xanthine (Sigma) and phosphoric acid salt-BS (PBS) preparation.In addition, with all test compounds freezing in the DMSO of 20mmol/L solution, be used for experiment after thawing when needing.Method is following: after the diluting soln of test compounds being added in the 11.1mU/mL enzyme solution of 90 μ L, this mixture was mixed back incubation 10 minutes.In order to start reaction, the 200 μ mol/L substrate solutions of 100 μ L are added to wherein, after 10 minutes,, measure absorbancy then at the 283nm place through adding the 0.5mol/L sulfuric acid stopped reaction of 500 μ L.The ultimate density of test compounds is single concentration, and 10 μ mol/L are used for initial screening in single hole, and 6 kinds of concentration: 10,1 μ mol/L, and 100,10,1nmol/L, the 100pmol/L double is used for analyzing, the 50% inhibition concentration (IC that is used to analyze with calculating 50).Suppress per-cent according to computes.
Suppress per-cent (%)=(A-B)/(A-C) * 100
In formula, A is meant the absorbancy in the hole that does not have test compounds, and B is meant the absorbancy in the hole of test compounds, and C is meant the absorbancy in the blank well.
Through non-linear regression method, from the inhibition percentage calculation IC of each concentration 50Value.
2) UART1 restraining effect
Use the DMEM contain 10%FBS (to be supplemented with 0.05% Geneticin in the analysis; Nissui Pharmaceutical Co.; Ltd.), the HEK293 cell of forced expression URAT1 (HCS (human cell's system); (Fuji Biomedix)), as the HBSS of cleaning buffer solution and with the substituted HBSS of Na-glucono-(NaCl among the HBSS is replaced by the Na-glucono-).Use [8- 14C] uric acid (moravek) is as uric acid reagent, adds in the analysis buffer, and final concentration is 20 μ mol/L.Use compound of the present invention as test compounds; The 20mmol/L mother liquor (DMSO solution) of each test compounds is suitably diluted; Test compounds solution with dilution adds in the analysis buffer then, and final concentration is 100 μ mol/L, and the final concentration that comprises DMSO is 0.5%.
In order to prepare analysis plates, at first, the trypsinase-EDTA solution-treated of use 0.05% is peeled off the cell on the succeeding transfer culture petridish, then with 2 * 10 5The density kind of cells/well and was cultivated 2 days on Biocoat Poly-D-Lysine Cellware 24 orifice plates (BECTON DICKINSON).
For picked-up research, at first, substratum to be removed through suction, cell replaces with damping fluid the analysis buffer (37 ℃) of 1mL then with HBSS (37 ℃) washed twice.With cell preincubate 10 minutes.Then, remove damping fluid, add the ri ligand solution of 0.5mL, then cell was hatched 5 minutes at 37 ℃ of following incubations through suction.After the picked-up, remove radioisotope solution, and use ice-cold HBSS washed cell three times immediately, then through adding the 0.5mol/L NaOH dissolving of 0.5mL through suction.Lysate solutions is transferred in the bottle or 24 orifice plates that Betaplate uses, with liquid scintillator (Optiphase ' the Super Mix ' of 0.5mL; Perkin Elmer) mixes.Measure ri active (using β calculating instrument 1450).With the average counter in the contrast solution that does not comprise test compounds is 100%, through the average counter in the solution of confirming to comprise test compounds and the reduction per-cent of the average counter in the contrast solution, calculates and suppresses per-cent.
3) blood hyperuricemia (hypouricemic) effect
Use male 7 all SD rats in age (Charles River Japan) and be suspended in the Oteracil Potassium (Aldrich) in 1% gumwater, studied The compounds of this invention as the effect of test compounds to Oteracil Potassium inductive hyperuricemia.Test compounds is suspended in the 0.5%CMC-Na solution, then oral administration.Dosage is 10mg/kg or 50mg/kg.All give the volume of drug solns is 10mL/kg.The dorsal area of 250mg/kg Oteracil Potassium subcutaneous administration to rat, each test compounds oral administration after 1 hour.For control group, only use 0.5%CMC-Na solution as medium.After test compounds or matrix administration 2 hours, under etherization gather blood, according to the universal method separation of serum.Every group is handled number is 5.
The reagent of preparation is measured uric acid concentration below using.Deproteinated reagent prepares by following mode; The sodium wolframate of 100g is added in the flask of 2L, and 85% phosphoric acid and the 500mL crystal of 75mL really added in the flask of being furnished with reflux exchanger, and heated 1 hour.After the cooling, the little Huang-green solution that obtains accurately is diluted to 1L.Yellow soda ash-urea reagent prepares by following mode; The urea of 14g soda ash light and 14g is soluble in water, and the final volume of solution accurately is adjusted to 100mL.Phospho-wolframic acid color development reagent prepares in the solution of the above-mentioned deproteinated reagent of 4 times of dilutions of water.(10mg/dL:Kyokuto pharmaceuticalindustrial CO., LTD) as the uric acid standardized solution, the uric acid standardized solution with the pure water serial dilution also is used for typical curve then to use the UA standardized solution.
300 μ L serum or standard substance are added in the pure water of 2.1mL, in this solution, also add 150 μ L deproteinated reagent then, then mix.Behind the incubation 20 minutes, with this mixture under 3000rpm centrifugal 10 minutes.(0.5mL) adds in the supernatant of 1.5mL with yellow soda ash-urea reagent, and with this mixture incubation 20 minutes.Then, behind the color development reagent that adds 250 μ L, carried out incubation again 15 minutes.Measurement is in the absorbancy at 660nm place, and calculates the concentration of uric acid with typical curve.Reduction per-cent through the computes uric acid concentration.
Reduction per-cent (%)=(A-B)/A * 100 of uric acid concentration
In formula, A is meant the MV of blood uric acid concentration in the control group, and B is meant the MV of blood uric acid concentration in the test compounds treatment group.
Synthetic compound structural formula of the present invention, NMR and MS data and pharmaceutical research result are presented among the following table 8-15.
Figure S2006800373585D00491
Figure S2006800373585D00511
Figure S2006800373585D00521
Figure S2006800373585D00531
Figure S2006800373585D00541
Figure S2006800373585D00551
Figure S2006800373585D00561
Industrial applicibility
Nitrogen-containing heterocycle compound of the present invention or its pharmacy acceptable salt are the compound with X.O. restraining effect and uricosuric Excretion.Comprise these compounds and be expected to be used for gout or hyperuricemia as therapeutical agent as the pharmaceutical composition of the present invention of activeconstituents, or various diseases such as ischemia-reperfusion illness, inflammatory diseases, mellitus, cancer, arteriosclerosis, sacred disease etc.

Claims (13)

1. the nitrogen-containing heterocycle compound of following general formula (I) expression, or its pharmacy acceptable salt:
Figure FSB00000584882000011
Y wherein 1Expression N or C (R 4); Y 2Expression N or C (R 5);
R 4And R 5Expression can have the alkyl of halogen atom, perhaps Wasserstoffatoms independently;
R 1And R 2In expression cyanic acid or a formamyl;
R 1And R 2In another expression be selected from the aryl of phenyl and naphthyl, it can have the substituting group that is selected from alkyl, haloalkyl, alkoxyl group and halogen atom, wherein the certain substituted base on this aryl can form ring; Or being selected from the heterocyclic group of thienyl, thiazolyl or pyrryl, it can be replaced by alkyl or halogen atom; With
R 3Expression 5-tetrazyl or carboxyl; And condition is to work as Y 2Expression CR 5The time, Y 2Can with R 2Form benzene or pyridine ring together, this benzene or pyridine ring can have haloalkyl, halogen atom, cyanic acid or alkoxyl group as substituting group, and some the adjacent substituting groups on this benzene or the pyridine ring can form ring,
Wherein said alkyl is straight chain, side chain or cyclic C 1-12Alkyl,
Moieties in the said alkoxyl group is straight chain, side chain or cyclic C 1-12Alkyl,
Said haloalkyl is meant straight chain, side chain or cyclic C 1-12Alkyl is replaced by 1-3 halogen atom.
2. by the following general formula (I-A) or (I-B) nitrogen-containing heterocycle compound as claimed in claim 1 of expression, or its pharmacy acceptable salt:
Figure FSB00000584882000012
Figure FSB00000584882000021
R wherein 4aAnd R 5aRepresent Wasserstoffatoms or alkyl independently;
R 1aAnd R 2aIn one the expression cyanic acid;
R 1aAnd R 2aIn another the expression phenyl, it can have the substituting group that is selected from alkyl, haloalkyl, alkoxyl group and halogen atom, wherein the certain substituted base on this phenyl can form ring; Or being selected from the heterocyclic group of thienyl, thiazolyl or pyrryl, it can be replaced by alkyl or halogen atom; With
R 3Expression 5-tetrazyl or carboxyl.
3. nitrogen-containing heterocycle compound as claimed in claim 2 or its pharmacy acceptable salt, wherein R 1aExpression cyanic acid.
4. nitrogen-containing heterocycle compound as claimed in claim 3 or its pharmacy acceptable salt, wherein R 2aThe expression phenyl, it can have the substituting group that is selected from alkyl, haloalkyl, alkoxyl group and halogen atom, and wherein the certain substituted base on this phenyl can form ring; Or thienyl, it can be replaced by alkyl or halogen atom.
5. like each described nitrogen-containing heterocycle compound or its pharmacy acceptable salt, wherein R among the claim 2-4 3The expression carboxyl.
6. the nitrogen-containing heterocycle compound of following general formula (I-C) expression, or its pharmacy acceptable salt:
Figure FSB00000584882000022
Y wherein 1CExpression N or C (R 4C); Y 3Expression N or C (R 9); R 4CAnd R 9Represent alkyl or Wasserstoffatoms independently;
R 1CExpression cyanic acid or formamyl;
R 6, R 7And R 8Represent alkyl, haloalkyl, Wasserstoffatoms, halogen atom, cyanic acid or alkoxyl group independently; Perhaps R 6, R 7And R 8Any can form ring with adjacent substituting group; And
R 3Expression 5-tetrazyl or carboxyl,
Wherein said alkyl is straight chain, side chain or cyclic C 1-12Alkyl,
Moieties in the said alkoxyl group is straight chain, side chain or cyclic C 1-12Alkyl,
Said haloalkyl is meant straight chain, side chain or cyclic C 1-12Alkyl is replaced by 1-3 halogen atom.
7. nitrogen-containing heterocycle compound as claimed in claim 6 or its pharmacy acceptable salt, wherein R 1CExpression cyanic acid.
8. like claim 6 or 7 described nitrogen-containing heterocycle compounds or its pharmacy acceptable salt, wherein R 3The expression carboxyl.
9. a pharmaceutical composition comprises like each described nitrogen-containing heterocycle compound or its pharmacy acceptable salt among the claim 1-8 as activeconstituents.
10. pharmaceutical composition as claimed in claim 9, it is an xanthine oxidase inhibitor.
11. like claim 9 or 10 described pharmaceutical compositions, it is the uricosuric eccritic.
12. like claim 9 or 10 described pharmaceutical compositions, it is the medicament that is used to treat gout or hyperuricemia.
13. pharmaceutical composition as claimed in claim 9, it is the medicament that is used to treat ischemia-reperfusion illness, inflammatory diseases, mellitus, cancer, arteriosclerosis or sacred disease.
CN2006800373585A 2005-10-07 2006-10-03 Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same Expired - Fee Related CN101282936B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005295429 2005-10-07
JP295429/2005 2005-10-07
PCT/JP2006/319806 WO2007043401A1 (en) 2005-10-07 2006-10-03 Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same

Publications (2)

Publication Number Publication Date
CN101282936A CN101282936A (en) 2008-10-08
CN101282936B true CN101282936B (en) 2012-05-16

Family

ID=37942645

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800373585A Expired - Fee Related CN101282936B (en) 2005-10-07 2006-10-03 Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same

Country Status (7)

Country Link
US (1) US7947707B2 (en)
EP (1) EP1932833B1 (en)
JP (2) JP5222561B2 (en)
KR (1) KR20080066938A (en)
CN (1) CN101282936B (en)
CA (1) CA2623327A1 (en)
WO (2) WO2007043400A1 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101282936B (en) 2005-10-07 2012-05-16 橘生药品工业株式会社 Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
BRPI0717656A2 (en) * 2006-09-29 2014-04-29 Novartis Ag OXADIAZOL DIARYL DERIVATIVES
AU2007334436A1 (en) 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
AU2008218950A1 (en) * 2007-02-22 2008-08-28 Irm Llc Thiazole derivatives as modulators of G protein-coupled receptors
JP5330990B2 (en) * 2007-04-11 2013-10-30 キッセイ薬品工業株式会社 Nitrogen-containing heterocyclic compound and pharmaceutical composition containing the same
DK2133332T3 (en) 2007-04-11 2013-09-30 Kissei Pharmaceutical (AZA) DERIVATIVE DERIVATIVES AND THEIR USE FOR MEDICAL PURPOSES
CN101679244B (en) 2007-04-11 2014-01-01 橘生药品工业株式会社 5-membered heterocyclic derivative and use thereof for medical purposes
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
US7977358B2 (en) * 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
BR122018001851B1 (en) * 2007-08-13 2019-08-20 Monsanto Technology Llc PLANT PARASITE NEMATOID CONTROL METHOD
WO2009029632A1 (en) * 2007-08-27 2009-03-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
GB0719180D0 (en) * 2007-10-02 2007-11-14 Cambrex Karlskoga Ab New process
CA2696829C (en) * 2007-10-04 2017-07-04 Merck Serono S.A. Oxadiazole diaryl compounds
AU2008306885B2 (en) 2007-10-04 2013-12-05 Merck Serono S.A. Oxadiazole derivatives
ES2552764T3 (en) 2007-10-15 2015-12-02 The Salk Institute For Biological Studies Methods for the treatment of various diseases and conditions, and compounds useful for them
EP2842948A1 (en) 2007-11-27 2015-03-04 Ardea Biosciences, Inc. Novel compounds and compositions and methods of use
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
BRPI0914629A2 (en) * 2008-06-24 2019-09-24 Irm Llc compounds and methods for modulating g protein-coupled receptors
WO2010032200A1 (en) * 2008-09-18 2010-03-25 Pfizer Limited Amide compounds useful in therapy
JPWO2010044403A1 (en) * 2008-10-15 2012-03-15 キッセイ薬品工業株式会社 5-membered heteroaryl derivative and pharmaceutical use thereof
WO2010044410A1 (en) * 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 Biaryl isonicotinic acid derivative and medical application of same
WO2010044405A1 (en) * 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 Fused-ring derivative and medical application of same
WO2010044411A1 (en) * 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 Phenylisonicotinic acid derivative and use thereof for medical purposes
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
CN102395585A (en) 2009-01-30 2012-03-28 米伦纽姆医药公司 Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
PL2396321T3 (en) 2009-02-10 2015-10-30 Monsanto Technology Llc Compositions and methods for controlling nematodes
US8791142B2 (en) 2009-03-03 2014-07-29 Merck Serono S.A. Oxazole pyridine derivatives useful as S1P1 receptor agonists
CA2755132C (en) 2009-03-31 2018-02-13 Kissei Pharmaceutical Co., Ltd. Indolizine derivative and use thereof for medical purposes
CN101607923B (en) * 2009-07-21 2012-12-19 焦宁 Aromatic nitrile compounds or derivatives of same and synthetic method and application thereof
EP2558099A4 (en) * 2009-11-16 2013-07-17 Univ California San Francisco Kinase inhibitors
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
PE20131304A1 (en) 2010-08-11 2013-11-14 Millennium Pharm Inc HETEROARYLS AND THEIR USES
JP2013533318A (en) 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド Heteroaryl and uses thereof
JP5906191B2 (en) * 2010-09-29 2016-04-20 キッセイ薬品工業株式会社 (Aza) indolizine derivatives and their pharmaceutical use
UY33671A (en) 2010-10-13 2012-04-30 Millenium Pharmaceuticals Inc HETEROARILOS AND ITS USES
EP2630133A1 (en) * 2010-10-22 2013-08-28 Bayer Intellectual Property GmbH Novel heterocyclic compounds as pesticides
JPWO2012121168A1 (en) * 2011-03-04 2014-07-17 国立大学法人京都大学 Kinase inhibitor
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
HUE033019T2 (en) 2011-05-17 2017-11-28 Principia Biopharma Inc Tyrosine kinase inhibitors
US9115144B2 (en) 2011-08-24 2015-08-25 Kissei Pharmaceutical Co., Ltd. Fused heterocyclic derivative and pharmaceutical use thereof
US10214476B2 (en) 2011-12-30 2019-02-26 Ecole Nationale Superieure De Chimie De Clermont Ferrand Pain relief compounds
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
EP2634185B1 (en) 2012-03-02 2016-01-13 Sareum Limited TYK2 kinase inhibitors
CA2880178C (en) * 2012-07-27 2021-10-26 Sato Pharmaceutical Co., Ltd. Difluoromethylene compound
PT2892900T (en) 2012-09-10 2017-11-06 Principia Biopharma Inc Pyrazolopyrimidine compounds as kinase inhibitors
EP2914587A1 (en) * 2012-10-31 2015-09-09 Bayer CropScience AG Novel heterocyclic compounds as pest control agents
UA118254C2 (en) 2012-12-04 2018-12-26 Монсанто Текнолоджи Ллс NEMATOCIDAL WATER COMPOSITIONS OF SUSPENSION CONCENTRATE
JP2016508152A (en) 2013-01-10 2016-03-17 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Pyrazolyl-based carboxamides I as CRAC channel inhibitors
CN104884058A (en) 2013-01-10 2015-09-02 格吕伦塔尔有限公司 Pyrazolyl-based carboxamides II as CRAC channel inhibitors
TWI606048B (en) * 2013-01-31 2017-11-21 帝人製藥股份有限公司 Azolebenzene derivatives
ES2666918T3 (en) * 2013-03-29 2018-05-08 Teijin Pharma Limited Pyrazole derivative
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP3107544B1 (en) 2014-02-21 2020-10-07 Principia Biopharma Inc. Salts and solid form of a btk inhibitor
JP6615876B2 (en) * 2014-06-26 2019-12-04 モナシュ ユニヴァーシティ Enzyme interaction drug
BR112017001657B1 (en) * 2014-07-30 2023-01-17 Teijin Pharma Limited CRYSTAL, COMPOUND, PHARMACEUTICAL COMPOSITION, XANTHINE OXIDASE INHIBITOR, THERAPEUTIC OR PROPHYLACTIC AGENT FOR ONE OR MORE DISEASES, AND METHOD OF PRODUCTION IN THE SHAPE OF A CRYSTAL.
MY179339A (en) * 2014-07-30 2020-11-04 Teijin Pharma Ltd Crystal of azole benzene derivative
WO2016017826A1 (en) * 2014-07-30 2016-02-04 帝人ファーマ株式会社 Xanthine oxidase inhibitor
CA2970723C (en) 2014-12-18 2023-09-05 Principia Biopharma Inc. Treatment of pemphigus
KR102412146B1 (en) 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 Sodium channel blockers
TW201718572A (en) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 Tyrosine kinase inhibitors
CN106045898B (en) * 2016-06-28 2019-05-24 广东东阳光药业有限公司 A kind of Benzazole compounds and its preparation method and application
EP3478273A1 (en) 2016-06-29 2019-05-08 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
MX2022004713A (en) * 2019-10-30 2022-05-11 Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd Thiophene derivatives as xanthine oxidase inhibitors and application thereof.
EP4289422A1 (en) * 2021-02-04 2023-12-13 Kyushu University, National University Corporation Agent for suppressing il-31 production and pharmaceutical composition containing the same
TW202342456A (en) * 2022-04-27 2023-11-01 大陸商江蘇新元素醫藥科技有限公司 Compounds for reducing uric acid
CN116217508A (en) * 2022-12-15 2023-06-06 浙江工业大学 Oxadiazole compound for protecting beta cells to treat type II diabetes, and preparation method and application thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1051322A (en) * 1967-08-09
NL7017486A (en) 1969-12-15 1971-06-17
ZA707814B (en) * 1969-12-15 1972-07-26 Merck & Co Inc 2,5-disubstituted imidazoles and methods of preparing same
DE122008000051I1 (en) * 1990-11-30 2009-02-05 Teijin Ltd 2-ARYLTHIAZOL DERIVATIVE AND MEDICAMENT CONTAINING THEREOF
CA2396738C (en) * 1990-11-30 2006-08-29 Masatoshi Chihiro Thiazole derivatives as active superoxide radical inhibitors
FR2672050A1 (en) * 1991-01-30 1992-07-31 Atochem DIARYL-2,5-OXADIAZOLES 1,3,4-HYDROXYESTER, HYDROXYACIDE AND ACETOXYACIDE, PROCESS FOR THEIR SYNTHESIS.
JP3399559B2 (en) 1992-08-12 2003-04-21 帝人株式会社 2-phenyl heterocyclic compound
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
ATE229541T1 (en) * 1994-10-07 2002-12-15 Fujisawa Pharmaceutical Co CYCLIC HEXAPEPTIDES WITH ANTIBIOTIC ACTIVITY
WO1998008830A1 (en) * 1996-08-26 1998-03-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazole derivatives useful as selective inhibitors of pde-iv
ID21775A (en) 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical COMPOUND 1-PHENILPIRAZOL COMPOUNDS AND THE USE OF PHARMACIES
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
WO1998037068A1 (en) * 1997-02-21 1998-08-27 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
TR200003064T2 (en) * 1998-02-09 2001-02-21 Fujisawa Pharmaceutical Co; Ltd. New compound
JP2000001431A (en) * 1998-06-15 2000-01-07 Kotobuki Seiyaku Kk Uricosuric agent
HUP0102470A3 (en) * 1998-07-01 2002-05-28 Takeda Chemical Industries Ltd 1,3-azole derivatives as retinoid-associated receptor regulators and their use
DE19904406A1 (en) * 1999-02-04 2000-08-10 Bayer Ag Substituted pyrazole carboxylic acids
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
JP2001316378A (en) * 2000-04-28 2001-11-13 Takeda Chem Ind Ltd Benzamide derivative and its use
JP2002105067A (en) 2000-09-28 2002-04-10 Teijin Ltd 2-phenylthiazone derivative and medicine composition comprising the same as active ingredient
JP4160295B2 (en) * 2000-12-08 2008-10-01 武田薬品工業株式会社 Substituted thiazole derivatives having a 3-pyridyl group, method for producing the same, and use thereof
JP2002308860A (en) * 2001-04-06 2002-10-23 Chisso Corp Thiadiazole-ring-containing compound, liquid crystal composition containing the same, and liquid crystal display element using the composition
JP2003081832A (en) * 2001-06-26 2003-03-19 Takeda Chem Ind Ltd Function regulator for retinoid relative receptor
EP1432706A2 (en) * 2001-09-26 2004-06-30 Bayer Pharmaceuticals Corporation 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
JP2005162612A (en) * 2002-01-09 2005-06-23 Ajinomoto Co Inc Acylsulfonamide derivative
US7074816B2 (en) 2002-01-28 2006-07-11 Fuji Yakuhin Co., Ltd. 1 2 4-triazole compound
MXPA04008680A (en) 2002-02-19 2004-12-06 Pharmacia Italia Spa Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents.
CA2484233A1 (en) * 2002-05-13 2003-11-27 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
AU2004200420A1 (en) * 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
CA2527632A1 (en) * 2003-06-02 2004-12-09 F. Hoffmann-La Roche Ag Benzamide nitrile derivatives
AU2004260831A1 (en) * 2003-07-21 2005-02-10 Laboratoires Serono Sa Aryl dicarboxamides
GB0324159D0 (en) * 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
ATE461200T1 (en) * 2004-01-08 2010-04-15 Medivir Ab CYSTEIN PROTEASE INHIBITORS
CN101282936B (en) 2005-10-07 2012-05-16 橘生药品工业株式会社 Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
DK2133332T3 (en) 2007-04-11 2013-09-30 Kissei Pharmaceutical (AZA) DERIVATIVE DERIVATIVES AND THEIR USE FOR MEDICAL PURPOSES
CN101679244B (en) 2007-04-11 2014-01-01 橘生药品工业株式会社 5-membered heterocyclic derivative and use thereof for medical purposes
JP5330990B2 (en) 2007-04-11 2013-10-30 キッセイ薬品工業株式会社 Nitrogen-containing heterocyclic compound and pharmaceutical composition containing the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JP特开2000-1431A 2000.01.07
JP特开2002-105067A 2002.04.10
JP特表2005-529850A 2005.10.06

Also Published As

Publication number Publication date
US7947707B2 (en) 2011-05-24
US20090306396A1 (en) 2009-12-10
JPWO2007043401A1 (en) 2009-04-16
EP1932833B1 (en) 2012-08-01
WO2007043400A1 (en) 2007-04-19
EP1932833A1 (en) 2008-06-18
EP1932833A4 (en) 2010-08-25
JPWO2007043400A1 (en) 2009-04-16
WO2007043401A1 (en) 2007-04-19
KR20080066938A (en) 2008-07-17
JP5222561B2 (en) 2013-06-26
CN101282936A (en) 2008-10-08
CA2623327A1 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
CN101282936B (en) Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
JP2742372B2 (en) One of 5- (2- (4- (1,2-benzoisothiazol-3-yl) -1-piperazinyl) ethyl) -6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride Hydrate
JP2742370B2 (en) Method for producing arylpiperazinyl-heterocyclic compounds
Bahekar et al. Synthesis and anti-inflammatory activity of some [4, 6-(4-substituted aryl)-2-thioxo-1, 2, 3, 4-tetrahydro-pyrimidin-5-yl]-acetic acid derivatives
JP3220987B2 (en) 1-phenylpyrazole compounds and their pharmaceutical uses
CN101641339B (en) Compounds for the prevention and treatment of cardiovascular diseases
JP5330990B2 (en) Nitrogen-containing heterocyclic compound and pharmaceutical composition containing the same
JP2003534257A (en) Thrombopoietin mimic
CN103492028A (en) Novel sulfonaminoquinoline hepcidin antagonists
TW200922934A (en) Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use
CN105566276A (en) Benzo-hexatomic ring derivative used as DPP-4 inhibitor and application of benzo-hexatomic ring derivative
CN107151240A (en) Polysubstituted carbostyril compound of one class and its production and use
CN101426768A (en) Sulfonamide compounds useful as adg receptor modulators
CN108003155A (en) 3,4 dihydro -1H [1,8] naphthyridones of the homopiperidinyl substitution of antibacterial
CN103562191B (en) Nitrogenous saturated heterocyclic compound
CN109942476A (en) A kind of heteroaromatic class compound of the structural unit containing thiosemicarbazones and its preparation method and application
JPH01211582A (en) Benzodioxole derivative
US9802980B2 (en) Method for producing pyrazoles, novel pyrazoles and applications thereof
KR20140036312A (en) Novel compound having parp inhibitory activity
KR20010034406A (en) 2,3,4,5-Tetrahydro-1H[1,4]-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
FR2761071A1 (en) DERIVATIVES OF QUINOLEIN-2 (1H) -ONE AND DIHYDROQUINOLEIN-2 (1H) - ONE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
CN101010300A (en) 2-phenylpyridine derivative
JPH02191257A (en) Benzo-heterocyclic compound
JPS61251667A (en) Benzo-heterocyclic compound
WO1999002527A1 (en) Naphthyridine derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120516

Termination date: 20161003

CF01 Termination of patent right due to non-payment of annual fee